Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature

BACKGROUND: Nivolumab, an anti-programmed cell death protein 1 antibody, is commonly used as an immune checkpoint inhibitor in various cancers. Various adverse events are associated with these therapies, including hepatitis, dermatitis, and myocarditis. Myocarditis is a relatively rare but potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Feifei, Liu, Yang, Xu, Wei, Zhang, Changjing, Lv, Jianhong, Ma, Shaolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259021/
https://www.ncbi.nlm.nih.gov/pubmed/34225811
http://dx.doi.org/10.1186/s13256-021-02934-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259021/
https://www.ncbi.nlm.nih.gov/pubmed/34225811
http://dx.doi.org/10.1186/s13256-021-02934-y

Ejemplares similares